S2 E16.1 — How cost-effectiveness research on Widespread NIT screening in the U.S. Has Evolved

Mazen Noureddin describes how he became engaged in studying the cost-effectiveness of widespread NASH screening for diabetics in the US, and what he has found, while the Surfers comment on the value of this pivotal work.
()

After Mazen discusses how he became engaged in studying cost effectiveness in screening diabetes patients for NASH, he offers a 30,000-foot view of his findings and shares thoughts on what he plans to study next.

Stephen Harrison and Louise Campbell comment on the exceptional value of his work, after which Roger Green joins Louise in asking how COVID-19 might shape future cost effectiveness estimates.

This ground-breaking work has the potential to expand and redefine the role of population testing in the coming Fatty Liver pandemic.

How useful was this post?

Click on a star to rate it!

Average rating / 5. Vote count:

No votes so far! Be the first to rate this post.

Request A Transcript of This Episode
Request Transcript
First
Last

Join The Discussion…

Ask Our Panelists A Question…

Podcast Quesitonaire
Is your question directed towards one of our panelists?

If your question is answered in our next Podcast, would you like be tagged?

Join The Discussion!

Subscribe to our free emails. Receive access to our Discussion Group. Ask your questions directly to our "Surfers"